2. Academic Validation
  3. A drug screening toolkit based on the -1 ribosomal frameshifting of SARS-CoV-2

A drug screening toolkit based on the -1 ribosomal frameshifting of SARS-CoV-2

  • Heliyon. 2020 Aug;6(8):e04793. doi: 10.1016/j.heliyon.2020.e04793.
Yanqiong Chen 1 2 3,  Huan Tao 4,  Silan Shen 5 3,  Zhiyong Miao 1 3,  Lili Li 5 3,  Yongqian Jia 4,  Hu Zhang 5 3,  Xiufeng Bai 1 3,  Xinyuan Fu 1 3
Affiliations

Affiliations

  • 1 Laboratory of Human Disease and Immunotherapies, West China Hospital, Sichuan University, Chengdu, China.
  • 2 National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
  • 3 Clinical Institute of Inflammation and Immunology (CIII), Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China.
  • 4 Department of Hematology and Research Laboratory of Hematology, West China Hospital, Sichuan University, Chengdu, China.
  • 5 Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.
PMID: 32869005 DOI: 10.1016/j.heliyon.2020.e04793
Abstract

The -1 ribosomal frameshifting is vital for the translation of the open reading frame (ORF)1b in SARS-CoV-2. The products of ORF1b participate in viral replication. Therefore, changing the frameshift frequency reduces the survival of the virus. This study aimed to successfully develop a toolkit for screening Antiviral drugs. Finally, the FDA-approved drug library was screened, revealing that ivacaftor and (-)-Huperzine A worked well in changing the -1 ribosomal frameshifting of SARS-CoV-2 in vitro.

Keywords

-1 ribosomal frameshifting; Biomedical engineering; Drug screen; Microbial biotechnology; Molecular biology; Peptides; Protein engineering; SARS-Cov-2; Virology.

Figures
Products
Inhibitors & Agonists
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-B0496
    99.91%, Cathepsin Inhibitor
Other Products